Concord Healthcare Group (2453) H1 2024 earnings summary

Executive summary

• H1 2024 revenue fell 23.2% YoY to RMB219.0m; reported net loss narrowed 5.7% to RMB202.0m, while adjusted net loss excluding listing expenses narrowed 24.7% to RMB161.1m.

• Gross loss was RMB34.5m versus RMB35.0m, but gross margin weakened to -15.8% from -12.3% as lower revenue weighed on fixed-cost absorption.

Financial highlights

• Loss attributable to owners was RMB181.9m; basic and diluted loss per share was RMB0.25 versus RMB0.30 a year earlier.

• Other income and net gains rose to RMB43.6m from RMB5.2m, primarily reflecting subsidiary disposal gains of RMB36.9m and RMB4.1m.

• Selling, administrative and research expenses fell to RMB25.0m, RMB79.1m and RMB14.1m, respectively; listing expenses were RMB41.0m versus RMB0.2m.

• Finance costs were RMB53.7m versus RMB54.9m; loss before tax was RMB204.5m versus RMB218.4m.

Outlook and guidance

• Guangzhou proton-therapy equipment completed clinical trials; a Class A large medical equipment license was approved on Sep. 13, 2024, after the reporting period.

• Priorities include cloud-platform and AI product expansion, medical-device registrations, new customer development and broader customized services.

• H2 plans include expanding corporate health-screening and insurance partnerships; full use of Global Offering proceeds was targeted by Dec. 31, 2025.